SL
Silence Therapeutics plc
SLN · NASDAQ
$13.31 -0.52% (-$0.07)
1M -7.95%
Market Cap $640.0M
P/E Ratio -
Div. Yield -
ROE 106.90%
Piotroski F-Score Weak
1/9Valuation
0 /100
Expensive P/S 1,041.88x
P/B 16.64x
P/E N/A
Growth
22 /100
Declining Rev. growth 68.36%
Book val. growth 41.33%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 51.00%
FCF margin 6,893.22%
Net margin 9,755.61%
Quality
0 /100
Poor ROIC 176.21%
Asset turnover 0.01x
ROE 106.90%
Debt
33 /100
High Debt/Equity -0.00x
Current ratio 7.42x
Int. coverage N/A
Stability
41 /100
Moderate Beta 1.41x
Profitable years 0
Rev. volatility 90.95%
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o SLN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Iain Gladstone Ross
Employees
88
Headquarters
London
Prihajajoči dogodki
05 NOV.
Earnings
Upcoming earnings report